Legal Information & Trademarks

Singular Genomics Systems, Inc.

Patents & Trademarks

At Singular Genomics Systems, Inc. (“Singular”), we thrive on continuous innovation, discovering and developing new technologies to bring ground-breaking products and systems to our markets. Our commercial success depends on our ability to develop, manufacture, market and sell our products and we rely on patent, trademark, copyright, trade secret, and other intellectual property rights and contractual restrictions to protect our proprietary products and technologies. 

Notice of Patents, Designs, and Similar Rights

In accordance with Section 287(a) of Title 35 of the United States Code (35 U.S.C. §287(a)), Section 62 of the UK Patents Act 1977, Section 49(1) of the Irish Patents Act 1992 and any other comparable requirements in other jurisdictions, notice is hereby given that Singular’s products are protected by a variety of intellectual property rights including issued patents and pending patent applications, registered designs, and similar rights, details of which are provided below: 




G4 Kits




Px Kits


Information on Trademarks and Service Marks (“Marks”)

The logos and names of Singular Genomics Systems, Inc. (“Singular”) products or services identified below are protected by U.S. and international trademark and copyright laws. All trademarks are the property of Singular and below is a non-exhaustive list of trademarks and service marks belonging to Singular.  Trademark symbols reflect the status of the mark in the United States. 



    Singular Genomics™

    Singular Genomics Branding







    Max Read™


    All trademark name represented and listed owners are believed to be accurate, but not guaranteed to be so.  Other third party trademarks referenced on this Site, including but not limited to those listed below, are the property of their respective owners:

    • Illumina and NextSeq are trademarks or registered trademarks of Illumina, Inc.

    Drew Spaventa

    Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

    Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

    Max Reads Application Note